What are NS5A inhibitor drugs?

NS5A inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting HCV NS5A protein). 0 are currently marketed, with 5 more in clinical development.

NS5A inhibitor

0 marketed 2 in Phase 3 3 in Phase 2

This page covers all NS5A inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HCV NS5A protein, Hepatitis C virus NS5A protein, NS5A protein.

Targets

HCV NS5A protein · Hepatitis C virus NS5A protein · NS5A protein · HCV NS5A · NS5A

Phase 3 pipeline (2)

Placebo matching BMS-790052 · Bristol-Myers Squibb · Virology/Hepatology
BMS-790052 is a direct-acting antiviral agent that inhibits hepatitis C virus (HCV) NS5A protein, blocking viral replication.
BMS-790052 (Daclatasvir) · Bristol-Myers Squibb · Virology/Infectious Disease
Daclatasvir inhibits the hepatitis C virus NS5A protein, blocking viral replication and spread.

Phase 2 pipeline (3)

Elbasvir Oral Granules · Merck Sharp & Dohme LLC · Infectious Disease
Inhibits NS5A protein of hepatitis C virus
GF-001001-00 · Ferrer Internacional S.A. · Infectious Diseases
GF-001001-00 is a small molecule that targets the HCV NS5A protein.
Dasabuvir mini tablet · AbbVie · Infectious Disease
NS5A replication complex inhibitor